The association of T‐bet+ ABCs with a number of autoimmune diseases in mice and humans suggested that specific targeting could provide an opportunity to eliminate or curtail the activity of T‐bet+ ABCs, using agonist‐mediated A2aR targeting. The gene discussed is ADORA2A; the disease is autoimmune disease.